FDA requires REMS plan for 25 drugs, biologics
FDA issues a notice requiring the manufacturers of 25 high-risk drugs and biologics to submit a REMS plan.
In a notice published in the March 27
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Recent Videos
Related Content
